Article thumbnail

The Role of PTEN in Tumor Angiogenesis

By Stéphane Rodriguez and Uyen Huynh-Do


During the past 20 years, the phosphatase and tensin homolog PTEN has been shown to be involved in major physiological processes, and its mutation or loss is often associated with tumor formation. In addition PTEN regulates angiogenesis not only through its antagonizing effect on the PI3 kinase pathway mainly, but also through some phosphatase-independent functions. In this paper we delineate the role of this powerful tumor suppressor in tumor angiogenesis and dissect the underlying molecular mechanisms. Furthermore, it appears that, in a number of cancers, the PTEN status determines the response to chemotherapy, highlighting the need to monitor PTEN expression and to develop PTEN-targeted therapies

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A .K .O l s s o n ,A .D i m b e r g ,J .K r e u g e r ,a n dL .C l a e s s o n - W e l s h , “VEGF receptor signalling—in control of vascular function,”
  2. (2007). A Functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,”
  3. (1998). a m u r a ,J .G u ,K .M a t s u m o t o ,S .I .A o t a ,R .P a r s o n s ,a n d
  4. (2006). a n g ,G .Z .Z h e n g ,L .Z .R u ie ta l . ,“ M a t r i xm e t a l l o p r o -teinase 2 (MMP2) and MMP9 secreted by erythropoietinactivated endothelial cells promote neural progenitor cell migration,”
  5. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,”
  6. (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors,”
  7. (2003). Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells,”
  8. (2004). Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway,”ExperimentalCellResearch,vol.298,no.1,pp.167– 177,
  9. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer,”JournalofClinicalOncology,vol.27,no.35,pp.5924– 5930,
  10. (2009). Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist,”
  11. (2004). C.Daly,V.Wong,E.Burovaetal.,“Angiopoietin-1modulates endothelial cell function and gene expression via the transcription factor FKHR
  12. (2006). C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1,”
  13. (2010). Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies,”
  14. (2006). Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts,” Human Gene Therapy,
  15. (2010). de Bru¨ ıne,
  16. (1994). Dominantnegative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role
  17. (2010). Effe c to fw i l dt y p eP T E N gene on proliferation and invasion of multiple myeloma,”
  18. (2010). Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting,”
  19. (2008). Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion,”
  20. (2002). Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway,”
  21. (2007). EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis,”
  22. (2006). EphB4 provides survival advantage to squamous cell carcinoma of the head and neck,”
  23. (2005). Epidermal growth factor receptor, protein kinase B/Akt, and glioma responsetoerlotinib,”JournaloftheNationalCancerInstitute,
  24. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study,”TheLancetOncology,vol.10,no.3,pp.247–257,2009.
  25. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma,” Lung Cancer.
  26. (2010). Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer,”
  27. (2006). Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma,”
  28. (2008). F r e w ,C .R .T h o m a ,S .G e o r g i e ve ta l .
  29. (2006). Fibroblasts in cancer,”
  30. (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy,”
  31. (2006). Georgescu,“PTENtumorsuppressorassociateswithNHERF proteins to attenuate PDGF receptor signaling,”
  32. (2006). Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells,”
  33. (2008). Hirashima et al., “VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment,”
  34. (2005). Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin,”FASEB
  35. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular
  36. (2010). Inhibition of endothelial nitric oxide synthase by the lipid phosphatase
  37. (1995). Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding,”
  38. (2004). Korff,F .S c h a ffner et al., “Inhibition of tumor growth and angiogenesis by soluble
  39. (2011). Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2—overexpressing locally advanced breast cancers,”
  40. (2010). M o l i n a ,F .C .M o r a l e s ,Y .H a y a s h i ,K .D .A l d a p e
  41. (2009). M.D.Prados,S.M.Chang,N.Butowskietal.,“PhaseIIstudy of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiformeorgliosarcoma,”JournalofClinicalOncology,vol.
  42. (2009). M.Kimura,Y.Kato,D.Sanoetal.,“SolubleformofephrinB2 inhibits xenograft growth of squamous cell carcinoma
  43. (2003). Marsh,C.D .M orrisonetal.,“Germlineinactivation of PTEN and dysregulation of the phosphoinositol3- kinase/Akt pathway cause human Lhermitte-Duclos disease in adults,”
  44. (2006). Mashino et al., “Activation of PI3K/Aktsignalingand hormoneresistanceinbreastcancer,”
  45. (2000). Mechanisms of angiogenesis and arteriogenesis,”
  46. (2010). Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype,”
  47. (2010). MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity,”
  48. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer,”
  49. (2009). miR21 as a key regulator of oncogenic processes,”
  50. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation,”
  51. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors,” The New England
  52. (1998). Molecular distinction and angiogenic interaction between embryonic arteriesandveinsrevealedbyephrin-B2anditsreceptorEphB4,”
  53. (2010). Molecular markers associated with response to chemotherapy in gastroentero-pancreatic neuroendocrine tumors,”
  54. (2003). Molecular regulation of vessel maturation,”
  55. (2009). Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer,”
  56. (2001). Multiple roles of Eph receptors and ephrins in neural development,”
  57. (1998). Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline
  58. (2007). Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor,”
  59. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway,”
  60. (2010). Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth,”
  61. Orsenigo et al., “PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients,”
  62. (2008). Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination andextendssurvivalinmice,”MolecularCancerTherapeutics,
  63. (2002). Oxygen-dependent and -independent regulation of HIF-1alpha,”
  64. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,”
  65. (2010). Phosphatidylinositol3-kinase mediates pain behaviors induced byactivation of peripheral ephrinBs/EphBs signaling in mice,”
  66. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers,”
  67. (2007). PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis,”
  68. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies,”
  69. (2010). PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response andsurvivalinpatientswithHER2-positivemetastaticbreast cancer,”
  70. (2008). Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study,”
  71. (2007). Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling,”
  72. (2009). Prdx1 inhibits tumorigenesis via regulating
  73. (2001). Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo,”
  74. (2007). PtdIns(3,4,5)P3-dependent and -independent roles for PTEN in the control of cell migration,”
  75. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,”
  76. (2001). PTEN and myotubularin: novel phosphoinositide phosphatases,”
  77. (2009). PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer,”
  78. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of
  79. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients,”
  80. (2010). PTEN regulates angiogenesis and VEGF expression through phosphatasedependent and -independent mechanisms in
  81. (2010). PTEN silencing reverses aging-related impairment of angiogenesis in microvascular endothelial cells,”
  82. (2010). PTEN status in advanced colorectal cancer treated with cetuximab,”
  83. (2006). Receptor tyrosine kinase EphB4 is a survival factor in breast cancer,”
  84. Regulation of angiogenesis by Eph-ephrin interactions,”
  85. (2004). Regulation of cell migration by the C2 domain of the tumor suppressor
  86. (2006). Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction,”
  87. (2001). Regulation of theacutemyeloidleukemiacelllineOCI/AML-2byendothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system,”
  88. (2002). Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells,”
  89. (2009). Resistance to EGF-R (erbB-1) and VEGF-R modulating agents,”
  90. (1995). S a t o ,Y .T o z a w a ,U .D e u t s c he ta l . ,“ D i s t i n c tr o l e so f the receptor tyrosine kinases
  91. (2008). SDF-1α/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway,”
  92. (1999). Shc and FAK differentially regulate cell motility and directionality modulated by PTEN,”
  93. (2009). Sucker et al., “Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma,”
  94. (2010). Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells,”
  95. (2009). Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab,”
  96. (2008). Targeting phosphoinositide 3-kinase—moving towards therapy,”
  97. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations,”
  98. (2011). Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism,”
  99. (1996). The degradation of human endothelial cellderived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases,”JournalofBiologicalChemistry,vol.271,no.17,
  100. (2004). The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface,”
  101. (2007). The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology,”
  102. (2010). The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation,”
  103. (2009). The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly,”
  104. (2009). Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation,”
  105. (1986). Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing,”
  106. (2003). u s s o l a t i ,I .D e a m b r o s i s ,S .R u s s o ,M .C .D e r e g i b u s ,a n d G. Camussi, “Altered angiogenesis and survival in human tumor-derived endothelial cells,”
  107. (2001). v a n ,K .K o n d o ,H .Y a n ge ta l . ,“ H I F α targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing,”
  108. (1998). Vascular endothelial growth factor regulates endothelial cell survivalJournal of Oncology 9 through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation,”
  109. (2007). VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt-dependent pathway to modulate
  110. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and
  111. (2010). VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma,” Modern Pathology,
  112. (2004). W o n g ,J .A .K e r n e r ,a n dD .G .J a y ,“ C o n v e r g e n ta n d divergent signaling mechanisms of growth cone collapse by ephrinA5 and slit2,” J o u r n a lo fN e u r o b i o l o g y ,
  113. (2006). Yoshie et al., “PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib,”